390 related articles for article (PubMed ID: 36319568)
21. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
[TBL] [Abstract][Full Text] [Related]
22. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
[TBL] [Abstract][Full Text] [Related]
23. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
24. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.
Stolz S; Roncador M; Rösler W; Zenz T; Manz MG; Müller AMS; Widmer CC
Swiss Med Wkly; 2022 Jun; 152():w30186. PubMed ID: 35752964
[TBL] [Abstract][Full Text] [Related]
25. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
26. Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K; Subklewe M; Locke FL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
[TBL] [Abstract][Full Text] [Related]
27. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.
Barata A; Hoogland AI; Kommalapati A; Logue J; Welniak T; Hyland KA; Eisel SL; Small BJ; Jayani RV; Booth-Jones M; Oswald LB; Gonzalez BD; Kirtane KS; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
Transplant Cell Ther; 2022 Jul; 28(7):401.e1-401.e7. PubMed ID: 35580732
[TBL] [Abstract][Full Text] [Related]
28. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
29. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
[TBL] [Abstract][Full Text] [Related]
30. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy.
Johnson PC; Neckermann I; Sadrzadeh H; Newcomb R; El-Jawahri AR; Frigault MJ
Transplant Cell Ther; 2024 May; 30(5):490-499. PubMed ID: 38412928
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis.
Akhtar OS; Sheeba BA; Azad F; Alessi L; Hansen D; Alsina M; Baz R; Shain K; Grajales Cruz A; Castaneda Puglianini O; Liu H; Blue B; Nishihori T; Al Jumayli M; Extermann M; Locke FL; Mhaskar R; Freeman CL
J Geriatr Oncol; 2024 Mar; 15(2):101628. PubMed ID: 37723045
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
Costa BA; Flynn J; Nishimura N; Devlin SM; Farzana T; Rajeeve S; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Hultcrantz M; Korde N; Lesokhin AM; Shah UA; Tan CR; Giralt SA; Usmani SZ; Nath K; Mailankody S
Blood Cancer J; 2024 May; 14(1):84. PubMed ID: 38802346
[TBL] [Abstract][Full Text] [Related]
33. Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy.
Gaffney KJ; Davis JA; McGann M; Edwards K; Ahmed Z; Butcher C; Greenwell B; Hess BT; Hashmi H
J Oncol Pharm Pract; 2024 Jan; 30(1):151-158. PubMed ID: 37097891
[TBL] [Abstract][Full Text] [Related]
34. Early granulocyte colony stimulating factor administration increases the risk of cytokine release syndrome in acute lymphoblastic leukemia patients receiving anti-CD19 chimeric antigen receptor T-cell therapy.
Cao M; Han S; Qiu Y; Zhou L; Su Y; Tu S; Li Y
Hematol Oncol; 2023 Dec; 41(5):933-941. PubMed ID: 37259483
[TBL] [Abstract][Full Text] [Related]
35. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
36. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
Zhou L; Fu W; Wu S; Xu K; Qiu L; Xu Y; Yan X; Zhang Q; Zhang M; Wang L; Hong R; Chang AH; Yu J; Fu S; Kong D; Li L; Wang Y; Li Z; Jiang H; Huang J; Liu Z; Su N; Wei G; Hu Y; Huang H
Br J Haematol; 2023 Aug; 202(3):517-524. PubMed ID: 37192741
[TBL] [Abstract][Full Text] [Related]
37. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
Front Immunol; 2022; 13():858021. PubMed ID: 35432352
[TBL] [Abstract][Full Text] [Related]
38. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
39. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy.
Wang X; Qi Y; Li H; Liu F; Cao J; Chen W; Wang Y; Qi K; Yan Z; Zhu F; Li Z; Cheng H; Xu K
Front Immunol; 2022; 13():943004. PubMed ID: 36081517
[TBL] [Abstract][Full Text] [Related]
40. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R
Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
